Back to 2014 Annual Meeting Display Posters
Is Surgical Aortic Valve Replacement Activity Really Stimulated by Trans-Catheter Alternatives in Active Centers?
Mark A. Groh1, Steve W. Ely1, Oliver A. Binns1, Alan M. Johnson1, Wendy Westling2, Gerard L. Champsaur3.
1Asheville Heart, Asheville, NC, USA, 2MIssion Hospital, Asheville, NC, USA, 3Mission Hospital, Asheville, NC, USA.
OBJECTIVE: Purpose: Institutional support for transarterial aortic valve replacement (TAVR) is partly based on the “Halo
effect” of increased surgical aortic valve replacement (SAVR) reported in centers participating in early US trials. We evaluated a mature regional program performing over 400 valve procedures annually to assess the reality of this purported effect on high risk patients undergoing SAVR.
METHODS: From January 2008 through December 2012, 154 octogenarians (36.6% female) underwent SAVR via sternotomy with cardiopulmonary bypass while a multidisciplinary valve clinic (MVC) was established in September 2011. Global patient demographics are shown in Table I, and have remained identical in both Groups: “I” before and “II” after establishing the valve clinic. A concomitant coronary bypass procedure (CABG)was performed in a total of 80 patients with the same frequency in both Groups.
RESULTS: Early mortality was 5.8% and 7.6% in groups I and II, respectively (p=0.68) and between-groups differences did not reach statistical significance in STS risk scores, stroke rate, bleeding, renal failure, or arrhythmias. Number of high risk patients undergoing SAVR averaged 3.2 and 3.4 per month, unchanged over time in Group II. Hospital length of stay remained stable although patients requiring concomitant CABG had similar significantly longer hospital stays in both groups (10.1 vs. 7.7days, p<0.02). Global probability of survival is depicted in Graph 1 with 4-year survival at 71.36%.
CONCLUSIONS: So far, commitment of resources to a MVC has not increased the pool of patients referred for SAVR at our institution. This may be due to our history of aggressive management of older patients with aortic stenosis or to the short-term observation of the changes. Measuring the growth of SAVR from MVCs is mandatory to assess resource allocation and quality outcomes. This report can help other mature programs understand the realistic benefits of an integrated valve clinic program.
| Variable | Mean | Std. Dev. | 95% C.I. | Range |
| Age, years | 83.4 | 3.16 | 82.9-83.9 | 80-96 |
| BMI | 27.8 | 6.1 | 26.9-28.8 | 14.1-55.7 |
| EF, % | 50.8 | 10.8 | 49.1- 52.5 | 13-75 |
| MPG, mmHG | 43.6 | 17.2 | 40.8-46.4 | 12-10 |
| AVA, cm2 | 0.71 | 0.21 | 0.65-0.77 | 0.3-1.3 |
| Pre-existing Conditions | ||||
| Hypertension | 84% | Atrial Fibrillation | 13% | |
| Diabetes | 28% | Smoking History | 8% | |
| Dyslipidemia | 25% | Chronic lung disease | 6% |
Back to 2014 Annual Meeting Display Posters

